Serum Levels of S100A11 and MMP-9 in Patients with Epithelial Ovarian Cancer and Their Clinical Significance
Table 2
The relationship between the serum levels of S100A11 and MMP-9 and clinicopathological characteristics in patients with EOC.
Clinical variable
No. of patients
S100A11 (ng/mL) Median (range)
valuea
MMP-9(ng/mL) Median (range)
valuea
All cases
111
Age at diagnosis(years)
0.201
0.136
<51
55
11.01 (4.46-32.74)
165.53 (35.21-688.99)
≥51
56
15.60 (5.60-38.86)
199.61 (59.01-475.02)
Histological type
0.32
0.678
Serous
80
13.41 (4.46-32.22)
180.51 (35.21-475.02)
Mucinous
10
12.58 (7.60-32.75)
195.80 (63.42-688.99)
Endometrioid
13
10.75 (6.38-38.86)
151.90 (47.22-422.59)
Clear cell tumor
8
12.32 (8.13-29.86)
153.26 (55.59-248.06)
Tumor grade
0.93
0.978
G1
8
13.02 (8.03-22.62)
182.96 (63.42-441.95)
G2
23
11.71 (6.38-32.22)
156.85 (47.22-422.59)
G3
80
13.02 (4.46-38.86)
181.38 (35.21-688.99)
Lymph node metastasis
0.01
0.007
Negative
60
12.58 (4.46-32.75)
154.03 (35.21-688.99)
Positive
51
14.24 (5.60-38.86)
204.23 (63.47-475.02)
FIGO stage
<0.001
<0.001
I, II
30
10.00 (6.38-29.86)
139.94 (43.82-246.16)
III, IV
81
14.15 (4.46-38.86)
199.65 (35.21-688.99)
Serum CA125 level (U/mL)
0.04
0.002
<35
26
12.32 (4.46-31.26)
154.44 (35.21-441.95)
≥35
85
14.29 (6.20-38.86)
199.59 (43.82-688.99)
Chemotherapy resistanceb
0.01
<0.001
Present
31
12.32 (4.46-31.26)
154.44 (35.21-441.95)
Absent
79
14.29 (6.20-38.86)
199.59 (43.82-688.99)
Ascites (mL)
0.01
0.045
<500
51
12.32 (4.46-31.26)
154.44 (35.21-441.95)
≥500
60
14.29 (6.20-38.86)
199.59 (43.82-688.99)
Two-tier system
0.52
0.29
I type
45
12.76 (6.38-38.86)
156.85 (47.22-441.95)
II type
66
13.19 (4.46-32.75)
183.62 (35.21-688.99)
Residual tumor size (cm)
0.03
0.002
<2
86
12.76 (4.46-38.86)
167.70 (35.21-688.99)
≥2
25
15.81 (5.60-31.17)
244.50 (83.18-344.22)
aThe Mann–Whitney and Kruskal-Wallis nonparametric tests were used to compare different groups. bOne patient with stage I and Grade I did not undergo chemotherapy.
